Headshots of researchers involved in the BANDIT trial in new onset diabetes
Research Spotlight

Groundbreaking study finds JAK inhibitor baricitinib slows type 1 diabetes progression

World-first study findings by Australian researchers show a daily pill containing the JAK inhibitor baricitinib can preserve insulin production in people newly diagnosed with T1D. Published in the December issue of the New England Journal of Medicine, findings were co-authored by Thomas Kay, MBBS, PhD,  and Helen Thomas, PhD, St.

Read more